What is IMCR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.51B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IMCR?

P/E (TTM) is n/a and 52-week range is $27.50 to $40.71 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IMCR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IMCR?

The company profile lists revenue (TTM) near $430M, net income (TTM) near -$1.81B, EPS (TTM) near -$0.37 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Immunocore Holdings PLC based, and what identifiers does Chartloom list?

The company context section lists headquarters in Abingdon, Oxfordshire, GB, 50.9M shares outstanding, ISIN US45258D1054 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Immunocore Holdings PLC (IMCR) Stock Analysis & Quote

Immunocore Holdings PLC

$IMCR

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company is headquartered in Abingdon, Oxfordshire and currently employs 524 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The firm has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Employees

524

Website

www.immunocore.com/

IPO

2021-02-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)